Bristol-Myers Squibb Company

NYSE: BMY
$58.71
-$0.67 (-1.1%)
Closing Price on December 9, 2024

BMY Stock Chart and Intraday Price

BMY Stock Data

Asset Type Stock
Exchange NYSE
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 430 E. 29TH STREET, 14 FLOOR, NEW YORK, NY, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 102,909.25M USD
Shares Outstanding 2,022,190,000
Bristol-Myers Squibb Company is a global biopharmaceutical firm focused on discovering, developing, and delivering innovative medicines for a range of serious diseases. With a rich history dating back to 1887, it specializes in treatments across hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience fields. Its portfolio includes notable drugs like Eliquis, Opdivo, and Sprycel, targeting conditions from cancer to multiple sclerosis. The company markets its products to a variety of clients, including hospitals, pharmacies, and government agencies, aiming to improve patient health outcomes worldwide.

BMY Articles

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Donald Trump’s victory is positive for the stock...
Investors can buy these five top passive income dividend stocks and hold them for the long haul. Top Wall Street firms rate them all at Buy.
24/7 Wall St. Insights: AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are now questioning the pharma’s pipeline, raising...
These six high-yield dividend stocks are universally loved by investment professionals and they now offer reasonable entry points.
AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and reliable stock.
24/7 Wall St. Insights The seemingly endless political season is almost over. It’s possible we won’t know the winner for a while. Sit back and let dividends do the heavy lifting for a simple,...
Here are three quality blue chip passive income stocks that are still reasonably priced and are rated Buy at top Wall Street firms.
24/7 Wall St. Insights Baby boomers are overweighted to stocks and stock mutual funds. Growth stocks and risky assets could be crushed in a panic sell-off. Sit back and let dividends do the heavy...
24/7 Wall St. Insights The 2025 Social Security COLA will be only 2.5%. The COLA increase will equal about $50 per person each month. Sit back and let dividends do the heavy lifting for a simple,...
Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are neither, or rather they are a mix of the two as everyone wants to buy a stock at...
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what the company's prospects are for the next decade of growth.
The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry. The...
24/7 Wall St. Insights Dividend stocks are starting to outperform in the second half of 2024. Lower interest rates should be a strong tailwind for companies that pay dependable dividends. Grab our...
24/7 Wall St. Insights Quality dividend stocks can deliver dependable passive income for years. Dividend stocks could get a big boost as interest rates come down over the next two years. Take...
The concept of value stocks are easy to understand. In definition, value stocks are stocks that trade below their intrinsic value. Easy enough – that’s what most investors are seeking, after all....